Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Eli Lilly and Company
Eisai Inc.
Gilead Sciences
Exelixis